Free Trial

Cadre (CDRE) Competitors

Cadre logo
$30.99 +1.36 (+4.58%)
Closing price 03:59 PM Eastern
Extended Trading
$31.06 +0.07 (+0.24%)
As of 06:55 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

CDRE vs. GKOS, BLCO, SLNO, TMDX, NVST, LIVN, WRBY, INSP, PRCT, and LMAT

Should you be buying Cadre stock or one of its competitors? The main competitors of Cadre include Glaukos (GKOS), Bausch + Lomb (BLCO), Soleno Therapeutics (SLNO), TransMedics Group (TMDX), Envista (NVST), LivaNova (LIVN), Warby Parker (WRBY), Inspire Medical Systems (INSP), PROCEPT BioRobotics (PRCT), and LeMaitre Vascular (LMAT). These companies are all part of the "medical equipment" industry.

Cadre vs. Its Competitors

Cadre (NYSE:CDRE) and Glaukos (NYSE:GKOS) are both medical equipment companies, but which is the better investment? We will compare the two businesses based on the strength of their media sentiment, earnings, analyst recommendations, dividends, valuation, institutional ownership, profitability and risk.

Cadre currently has a consensus target price of $31.50, indicating a potential upside of 1.66%. Glaukos has a consensus target price of $127.42, indicating a potential upside of 35.25%. Given Glaukos' stronger consensus rating and higher probable upside, analysts plainly believe Glaukos is more favorable than Cadre.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Cadre
1 Sell rating(s)
0 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
2.00
Glaukos
1 Sell rating(s)
2 Hold rating(s)
10 Buy rating(s)
1 Strong Buy rating(s)
2.79

Cadre has a beta of 1.31, meaning that its share price is 31% more volatile than the S&P 500. Comparatively, Glaukos has a beta of 0.78, meaning that its share price is 22% less volatile than the S&P 500.

Cadre has a net margin of 6.65% compared to Glaukos' net margin of -21.43%. Cadre's return on equity of 12.08% beat Glaukos' return on equity.

Company Net Margins Return on Equity Return on Assets
Cadre6.65% 12.08% 5.60%
Glaukos -21.43%-8.59%-6.61%

Cadre has higher revenue and earnings than Glaukos. Glaukos is trading at a lower price-to-earnings ratio than Cadre, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Cadre$567.56M2.22$36.13M$0.9432.96
Glaukos$383.48M14.09-$146.37M-$1.65-57.10

In the previous week, Glaukos had 10 more articles in the media than Cadre. MarketBeat recorded 12 mentions for Glaukos and 2 mentions for Cadre. Cadre's average media sentiment score of 1.53 beat Glaukos' score of 1.50 indicating that Cadre is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Cadre
2 Very Positive mention(s)
0 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Very Positive
Glaukos
11 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Very Positive

44.0% of Cadre shares are held by institutional investors. Comparatively, 99.0% of Glaukos shares are held by institutional investors. 31.5% of Cadre shares are held by company insiders. Comparatively, 5.8% of Glaukos shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Summary

Cadre beats Glaukos on 10 of the 17 factors compared between the two stocks.

Get Cadre News Delivered to You Automatically

Sign up to receive the latest news and ratings for CDRE and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding CDRE and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

CDRE vs. The Competition

MetricCadrePROTECTION IndustryIndustrials SectorNYSE Exchange
Market Cap$1.20B$2.16B$7.65B$20.94B
Dividend Yield1.28%1.87%4.56%3.58%
P/E Ratio32.9619.0625.7926.59
Price / Sales2.224.0399.7055.16
Price / Cash20.9269.9828.3923.54
Price / Book3.794.084.095.45
Net Income$36.13M$110.39M$796.69M$992.10M
7 Day Performance6.67%1.46%0.60%2.62%
1 Month Performance-5.51%-1.97%1.19%2.51%
1 Year Performance-11.47%24.86%27.76%12.94%

Cadre Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
CDRE
Cadre
2.0185 of 5 stars
$30.99
+4.6%
$31.50
+1.7%
-16.7%$1.20B$567.56M32.962,284
GKOS
Glaukos
4.7647 of 5 stars
$86.94
+2.7%
$127.42
+46.6%
-30.9%$4.85B$383.48M-52.69780Positive News
BLCO
Bausch + Lomb
2.2558 of 5 stars
$13.66
+0.1%
$15.56
+13.9%
-10.1%$4.83B$4.79B-17.5113,500
SLNO
Soleno Therapeutics
4.5809 of 5 stars
$85.76
+4.1%
$113.30
+32.1%
+34.6%$4.38BN/A-20.7130News Coverage
Analyst Forecast
Analyst Revision
TMDX
TransMedics Group
2.8881 of 5 stars
$127.26
+11.1%
$123.00
-3.3%
-31.3%$3.90B$441.54M65.94210Positive News
NVST
Envista
3.8535 of 5 stars
$20.19
-0.3%
$20.92
+3.7%
+13.5%$3.36B$2.51B63.0812,300
LIVN
LivaNova
1.7935 of 5 stars
$49.56
+1.5%
$59.29
+19.6%
+14.2%$2.67B$1.25B-12.742,900Positive News
Analyst Forecast
WRBY
Warby Parker
2.2898 of 5 stars
$23.25
-0.4%
$24.06
+3.5%
+85.6%$2.44B$771.32M-332.023,780Positive News
INSP
Inspire Medical Systems
4.9348 of 5 stars
$79.62
+0.6%
$173.31
+117.7%
-51.0%$2.34B$802.80M46.021,246Positive News
Short Interest ↓
PRCT
PROCEPT BioRobotics
3.608 of 5 stars
$38.77
+0.9%
$74.88
+93.1%
-52.8%$2.14B$224.50M-25.01430
LMAT
LeMaitre Vascular
2.2643 of 5 stars
$92.62
+0.4%
$98.00
+5.8%
+11.5%$2.09B$219.86M44.96490Positive News

Related Companies and Tools


This page (NYSE:CDRE) was last updated on 8/22/2025 by MarketBeat.com Staff
From Our Partners